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INTRODUCTION
Pancreatic endocrine tumours (PET) constitute a group of
various rare lesions occurring in five per million people per
year, with few surgeons experienced in their management.
These tumours are challenging on two fronts: treatment must be
directed first at the clinical syndrome caused by excess hormone
production; and second, to the tumour itself and possibility 
of malignancy. The tumours are named according to the hor-
mones they produce (Table 1). Although this group of diseases 
is termed PET, this can be misleading because many of the
tumours occur outside the pancreas (e.g. gastrinoma; vaso-
active intestinal polypeptide-secreting tumour (VIPoma); growth
hormone-releasing hormone-producing tumour (GHRHoma);
adrenocorticotropic hormone-producing tumour (ACTHoma);
somatostatinoma). Tumours can occur in either sporadic fashion or
in a hereditary fashion (multiple endocrine neoplasia (MEN)-1). In
the present article, the PET and MEN-1 will be reviewed, and new
advances in the area of imaging and treatment will be discussed.
INSULINOMA
The most common endocrine tumour of the pancreas is the
insulinoma, occurring in approximately one new case per
million population per year. Insulinomas synthesize and secrete
insulin autonomously in the presence of low blood glucose
levels, resulting in hypoglycaemia. Hypoglycaemic-induced
catecholamine surge symptoms include tremor, irritability,
weakness, tachycardia and hunger. Neuroglycopenic symptoms
include bizarre behaviour, seizures, speech disturbances and
coma. Relief of symptoms can be achieved by consumption of
carbohydrate-rich foods. The first exploration for malignant
insulinoma was undertaken by Dr W. J. Mayo and reported the fol-
lowing year by Wilder et al. in 1927.1 Whipple’s triad, associated
with an insulinoma, consists of (i) hypoglycaemic symptoms
while fasting; (ii) a blood glucose level < 50 mg/100 mL 
(2.8 mmol/L); and (iii) relief of symptoms following administration
of glucose.2
Monitoring the insulin/glucose ratio, initially by an overnight
fast, usually confirms the diagnosis. If the insulin/glucose ratio 
is > 0.3 (µU of insulin per mL/mg% glucose) this is diagnostic. 
If this is normal, a prolonged fast under medical supervision, for 
up to 72 h, is undertaken. Samples are drawn every 4–6 h 
during the fast, or whenever symptoms occur. C-peptide levels 
> 1.7 ng/mL and proinsulin levels > 30% also help confirm the
diagnosis when factitious hypoglycaemia is suspected. C-peptide and
insulin are the metabolic products of proinsulin cleavage within the
β cells. After endogenous hypersecretion of insulin the levels of 
C-peptide and proinsulin should be high, unlike that after exoge-
nous insulin preparations, when levels remain low.
Up to 90% of insulinomas are benign solitary tumours suit-
able for surgical resection or enucleation, whereas malignancy
is present in only 5–10% of cases.3
Insulinomas are distributed evenly throughout the pancreas in the
head, body and tail. Islet tumours that are multiple (MEN-1) or
larger ones in the distal gland are resected by distal pancreatectomy.
Smaller tumours not in direct approximation to the pancreatic
duct can be enucleated. A tumour in the proximal pancreas is
excised by enucleation with incision in the parenchyma made
parallel to the pancreatic duct to avoid duct injuries. Rarely,
large benign lesions in the head may be too large to safely enucleate
so they should be treated by pancreaticoduodenectomy. In
malignant insulinomas, resection of the primary and any accessi-
ble metastases should be undertaken. Tumours of the body/tail may
be resected by a distal pancreatectomy and splenectomy including
lymph nodes. Intraoperative insulin measurements have proved
useful for predicting the completeness of surgery in patients
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with insulinomas.4 Debulking of unresectable tumours can help
alleviate hypoglycaemic symptoms.
Medical treatment (diazoxide) can help improve hypogly-
caemic symptoms. Adjuvant chemotherapy (streptozotocin and
5-fluorouracil (5-FU)) and inhibition of tumour secretion by
synthetic somatostatin analogues (e.g. octreotide, lanreotide)
can help in patients with unresectable disease. Unfortunately
only approximately 50% of insulinomas respond to octreotide,
lacking somatotstatin receptors.
Misdiagnosis of insulinoma might occur in patients with adult
pancreatic nesidioblastosis. This rare disease causes hyperinsuli-
naemic hypoglycaemia with clinical and biochemical features
identical to those of insulinoma5 but neither localization studies nor
exploratory laparotomy for insulinoma reveal a discrete neo-
plastic lesion. Histopathology reveals the diagnosis of diffuse
hyperplasia of the islet cells. For this diagnosis to be established
preoperatively, selective pancreatic arterial stimulation with
calcium and hepatic venous sampling for insulin is required
(multiple high insulin levels). We use this test only when endo-
scopic ultrasound (EUS) fails to localize an insulinoma, which
currently occurs in fewer than 10% of cases.
GASTRINOMA (ZOLLINGER–ELLISON
SYNDROME)
Gastrinoma is the second most common islet cell secretory
tumour, having an incidence of 0.5–1.5 per million population per
year. In 1955 Zollinger and Ellison described a triad of (i) presence
of primary peptic ulcerations in unusual locations; (ii) excess
gastric secretions; and (iii) presence of an islet cell tumour of
the pancreas.6 This report preceded the discovery of gastrin, 
a polypeptide hormone and potent acid secretagogue that causes the
Zollinger–Ellison syndrome (ZES).7 A total of 25% of gastrinomas
occurs in the presence of MEN–1 syndrome. Any patient sus-
pected of having a gastrinoma should have serum calcium,
parathyroid and prolactin levels measured, even when there is
no family history of MEN-1.
The cause of this syndrome is hypersecretion of gastrin,
resulting in peptic ulceration of the upper gastrointestinal tract.
Gastrinoma should be suspected in any patient with peptic ulcer
disease who does not respond to conventional treatment, or 
in patients with ulcer disease and severe diarrhoea. Abdominal pain
and weight loss are common symptoms.
Fasting serum gastrin levels > 200 pg/mL are highly suggestive
of gastrinoma and a value > 1000 pg/mL is diagnostic in the
absence of achlorydria. Increased gastrin levels alone, however, 
are not sufficient, and other states (both ulcerogenic and non-
ulcerogenic) cause hypergastrinaemia (Table 2).
Gastric acid analysis allows differentiation between ulcero-
genic and non-ulcerogenic states. If the basal acid output is 
> 15 mEq/h, a diagnosis of gastrinoma is supported. Provoca-
tion testing with intravenous secretin causes a paradoxical stimu-
lation of gastrin in patients with gastrinomas and is the most
reliable diagnostic test (although secretin may be difficult to
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obtain). Once 2 U/kg of secretin is given, serum samples for
gastrin are taken for up to 30 min. Gastrinoma is diagnosed 
if gastrin levels increase 200 pg/mL over the baseline level. If
patients are already on H+–K+ adenosine triphosphatase
(ATPase) inhibitors, the drug should be stopped for 5 days
before gastrin levels are measured.
Preoperatively all patients should receive H+–K+ ATPase
inhibitors (omperazole/lansoprazole/pantoprazole) to treat the
gastric acid hypersecretion (also known as proton pump
inhibitors).
All patients with ZES without liver metastases are considered
operative candidates for a curative procedure. Preoperatively,
staging and localization are accomplished by computed tomogra-
phy (CT) scan, octreotide scan and EUS. Most gastrinomas are
found in the gastrinoma triangle which includes the pancreatic head,
uncinate and duodenum. If the patient has sporadic ZES with 
no evidence of a pancreatic tumour after thorough evaluation, 
a duodenotomy is performed because microgastrinomas may be the
sole cause of the hypergastrinaemia.8 The majority of patients
with sporadic ZES have been found to have duodenal primary
rather than pancreatic tumours, most of which cannot be identified
by preoperative localization studies.
A 6-cm longitudinal incision is made in the second part of 
the duodenum, allowing digital evaluation from the antrum to
the fourth part of the dudodeum. If no submucosal tumour is
palpable, the mucosa is everted and palpated in a meticulous
circumferential fashion to detect tumours as small as 1–2 mm
underneath the mucosa. Tumours < 4 mm are excised locally
but tumours 5 mm or larger are removed with a full thickness
ellipse of the duodenum and a margin around the tumour.9 We rou-
tinely perform a peripancreatic lymph node dissection including
nodes in the porta hepatis and along the common hepatic artery 
in patients with duodenal tumours or when a pancreatic tumour 
is 3 cm or larger. A whipple resection for ZES patients with
localized disease is not advocated when both the primary and
involved nodes can be removed by a lesser procedure, such as
enucleation.
If, despite extensive searching, no primary tumour is found,
several options remain: first, closure without intervention, other
than peripancreatic lymph node dissection, if the patient has
controlled acid hypersecretion; and second, parietal cell vago-
tomy. Cholecystectomy should be performed due to the possi-
bility of future unresectable disease amenable to treatment with
somatotstatin analogues that cause cholestasis and cholelithiasis.
Unresectable tumours can also be treated with chemotherapy
(doxorubicin; 5-FU; streptozocin). Antisecretory medication
should be continued indefinitely. Subsequent to the recognition that
occult duodenal tumours and lymph node metastases were the
most common aetiology of sporadic ZES, negative explorations
dramatically decreased and are now rare.

































































































































































































































































































































































































































































































































































Retained excluded antrum Pernicious anaemia
Gastric outlet obstruction Atrophic gastritis
Antral G cell hyperplasia/hyperfunction Short gut syndrome
Renal failure
GLUCAGONOMA
The glucagonoma syndrome, caused by excess glucagon secre-
tion, is associated with mild diabetes mellitus and a severe der-
matitis (necrolytic migratory erythema). The rash is typically
located on the lower abdomen, perineum and lower extremities.
Other symptoms include anaemia, malnutrition, glossitis, weight
loss, venous thrombosis and neuropsychiatric manifestations.
Glucagon excess enhances hepatic conversion of amino acid
nitrogen into urea nitrogen, resulting in low blood amino acid
levels.
Diagnosis is made when plasma glucagon levels are elevated;
usually > 500 pg/mL, with normal values being < 120 pg/mL.
Preoperatively the diabetes should be optimized and necro-
lytic migratory erythema treated. All patients should be given
subcuticular heparin cover due to the increased risk of thrombosis.
Treatment with octreotide can reverse the catabolic effects 
of glucagon excess and adequately prepares even the most
unfavourable patient for operation.
Most glucagonomas are malignant; metastases have been
found in 80% of patients with glucagonomas, and complete
resection is possible in only 30%. The majority of the tumours
originate in the body and tail and tend to be large at time of
exploration. Chemotheraputic treatment with 5-FU and strepto-
zotocin as well as dacarbazine (DTIC) have reported to help
incurable or recurrent disease.10 Octreotide may help control
hyperglycaemia and skin lesions. Hepatic embolization is the
best form of non-operative palliative treatment.11 The 5-year
survival rate is 50%.12 In patients with smaller glucagonomas,
usually detected incidentally by CT scans and without the syn-
drome, the results of resection for cure are much more
favourable.
VIPOMA (VERNER–MORRISON SYNDROME)
This syndrome has many names including the Verner–Morrison
Syndrome, WDHA (watery diarrhoea; hypokalaemia and either
achlorhydria or hypochlorhydria); and pancreatic cholera. Patients
present with large amounts of watery diarrhoea, averaging 3 L per
day. The diarrhoea contains excess potassium and bicarbonate
leading to a hypokalaemic acidosis. Patients are often lethargic,
and nauseated with muscular weakness. Other symptoms that
have been attributed to this syndrome include hypercalcaemia and
hyperglycaemia with cutaneous flushing observed in a minority.
Diagnosis is confirmed by elevated VIP levels of approxi-
mately 1000 pg/mL (normal: 0–75 pg/mL). The VIP secretion is
episodic so several fasting values may need to be measured.
Preoperatively fluid and electrolyte abnormalities are
corrected and octreotide used to decrease VIP levels, reducing
diarrhoea.
Definitive treatment is surgical excision of the tumour.
Because most VIPomas are in the distal pancreas, distal pancreatic
resection is performed. If no pancreatic tumour is found then the
retroperitoneum and adrenals should be thoroughly examined
for tumour. Fifty per cent of cases have metastases at presentation
and treatment involves palliative debulking. Octreotide and
indomethacin are useful in patients with unresectable tumours
for symptomatic control. The combination of streptozocin and
5-FU provides tumour response rates of > 50%.13 Of all the
functional PET, VIPomas appear to be most responsive to
octreotide. In some cases the use of octreotide may result in
tumour necrosis and long-term inhibition of metastatic growth. In
patients explored with metastatic disease, the gall bladder
should be routinely excised in anticipation of the use of long-
acting octreotide.
SOMATOSTATINOMA
The somatostatinoma syndrome occurs in less than 1 in 40
million people. Symptoms are non-specific and are caused by
somatostatin’s ability to inhibit the function of most of the
digestive organs. Symptoms include steatorrhoea, diabetes,
hypochlorhydria and cholelithiasis. Diagnosis is confirmed by
finding raised levels of plasma somatostatin, often > 10 ng/mL
(normal: 10–50 pg/mL).
Preoperatively, treatment of hyperglycaemia and malnutri-
tion should be addressed. Most somatostatinomas have been
located in the head of the pancreas and periampullary region.
Surgical treatment involves resection of the primary and usually
debulking hepatic metastases. Cholecystectomy is indicated 
due to the high incidence of gallstones with continuing
hypersomatostatinaemia.
The prognosis of advanced metastasizing somatostatinomas is
poor and average survival is < 24 months.14
GHRHOMA
Growth hormone-releasing hormone (GHRH) from the pancreas 
or other site (lung/gastrointestinal tract) causes the normal pituitary
to release enhanced amounts of growth hormone leading to
acromegaly. The sella is normal in size and magnetic resonance
imaging (MRI) and CT scans of the pituitary are also normal.
Many of these tumours express somatostatin receptors on the
cell surface, making treatment with octreotide possible.15 The
ideal therapeutic procedure is complete surgical resection of 
the lesion but if metastases have occurred, debulking is important
to decrease GHRH stimulation on the pituitary.11
ACTHOMA
Pancreatic ACTHomas account for 4–16% of all ectopic
Cushing’s syndrome. Because 96% of these PET are malignant, the
abdomen should be carefully imaged to look for a liver metastasis
or pancreatic mass. If none are present then the likelihood of a
pancreatic ACTHoma being the cause of ectopic ACTH is very
unlikely. The ACTHoma can occur in conjunction with malignant
gastrinoma. Pancreatic endocrine tumours that secrete both
gastrin and either CRF or ACTH are invariably aggressive
tumours and are associated with a poor prognosis.
PPOMA
Pancreatic polypeptide (PP) is a hormone secreted by pancreatic
endocrine cells in response to food, but its function is not com-
pletely understood. Pancreatic polypeptide is frequently secreted by
other PET so in order to classify a tumour as a PPoma more
than 50% of PP-secreting cells must be identified by immuno-
histochemistry.16 PPomas are associated with minimal or non-
specific clinical manifestations, or no clinical endocrine
syndromes. Patients present with weight loss, jaundice and
abdominal pain due to the mass effect of the tumour (Figs 1–3).
The diagnosis can be established by measuring fasting circulating
levels of PP: values > 300 pg/mL are diagnostic.
Surgical resection is the treatment of choice; debulking of
large tumours relieves mass effects and malignant behaviour.
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Chemotherapy with streptozotocin and somatostatin analogues
to treat residual disease have both been used.16,17
Non-functioning pancreatic endocrine tumours
Non functioning PET are not associated with a specific clinical syn-
drome. This can occur if the tumour does not secrete enough
hormone to produce a clinical syndrome or if the hormone
secreted causes no specific symptoms (e.g. PPoma). These
tumours present late, often with a palpable mass or with pres-
sure symptoms and a high malignancy rate (90%). More than
60% of cases have liver metastases at the time of diagnosis. The
lesion is commonly located in the head or neck of the pancreas. In
some cases portal hypertension may result from superior mesenteric
vein involvement. More recently, non-functioning PET have
been detected incidentally with CT scans while still being
resectable for cure based on staging with octreotide scanning.
An aggressive surgical approach including resection and
replacement of the superior mesenteric vein, if involved, is
considered justified in selected cases. Incurable disease can be
debulked, with surgical palliation of jaundice and gastric outlet
obstruction by biliary enteric or gastroenteric bypass, res-
pectively. Streptozocin and 5-FU have been used,18 as has
interferon.19 Five-year survival rates for metastatic non-
functioning PET averages 25–45%.16
Plasma chromogranin A is raised in 60–100% of both func-
tional and non-functional PET. This peptide can be used in
assessing tumour progression, relapse and tumour burden.
Serum chromogranin levels have proven to be a non-imaging
method to diagnose non-functional PET as well as to monitor
recurrence.20
Multiple endocrine neoplasia 1
MEN–1 syndrome is an autosomal dominant disorder caused 
by germline mutations in the MEN-1 gene localized on chro-
mosome 11q13.21 Its clinical expression involves the pancreas
(60–85%), parathyroids (85–100%), pituitary (40–70%) and
adrenal cortex (20–40%). Patients generally present with
primary hyperparathyroidism before pancreatic disease is
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Fig. 1. A 6 × 8-cm pancreatic head mass revealed by computed
tomography scanning in an asymptomatic patient. This was a non-
functioning pancreatic endocrine tumour producing pancreatic
polypeptide at 1600 pg/mL (normal: 0–300 pg/mL).
Fig. 2. Indium 111 octreoscan showing marked uptake in the pan-
creatic head tumour. There is normal tracer uptake by the liver,
spleen and kidney. Normal excretion of radioactivity into the gut is seen.
Fig. 3. Axial 3-D magnetic resonance imaging scan showing the pan-
creatic polypeptide-producing tumour in the head of the pancreas.
detected. Parathyroidectomy can be safely perfomed during the
same anaesthetic if hyperparathyroidism has not previously
been treated. Either a subtotal parathyroidectomy with a 60-mg
remnant or a total parathyroidectomy with autotransplantation
can be performed. Both should be accompanied by a cervical
thymectomy.22 Thymic carcinoids, usually in male patients, are a
rare but potentially lethal manifestation of MEN-1 and are an
indication for prophylactic thymectomy,23 in addition to the
need to excise supernumerary thymic parathyroids present in
15–20% of patients with MEN-1.
Multiple endocrine neoplasia-1 pancreatic disease is usually
multicentric. Of the functional tumours, gastrinomas are most
common, with the majority arising in the duodenum rather than in
the pancreas, followed by insulinomas. Other hormones that
may be secreted include VIP, glucagon, PP, calcitonin, or 5
hydroxytryptophan (carcinoid islet cell tumour). Since the
development of effective drug therapy to control acid secretion, the
management of gastrinomas in MEN-1 has become controver-
sial. Some have recommended a non-operative approach using
proton pump inhibitors to control symptoms because of a previ-
ously high failure rate to achieve surgical cure.24,25 However we
recommend surgical resection, despite the occurrence of multiple
tumours and the propensity for recurrence, to reduce the risk of
metastases.26 Once it was recognized that MEN-1 patients with ZES
usually had one or more duodenal gastrinomas, frequently with
local nodal metastases, a surgical procedure addressing these
tumours as well as those in the pancreas frequently was successful.
Because neuroendocrine tumours of the pancreas and duodenum
have malignant potential, the functional manifestations can actually
be eliminated with an appropriate procedure. Provided that the
tumour(s) have not metastasized to the liver and that the operation
is extensive enough to excise all sites of disease, these patients 
can be cured. Our current operation in MEN-1 patients with
ZES consists of distal pancreatectomy (invariably other PET
present), enucleation of any head or uncinate PET, which may
secrete gastrin (10–30%), duodenotomy with excision of one or
more gastrinomas (always present) and peripancreatic lymph
node dissection (metastatic nodes in 50%).
Surgical treatment of patients with insulinomas, glucagono-
mas, VIPomas and MEN-1 is generally advocated to obtain a
cure, again provided that no distant metastases are present. The
MEN-1 patients with hypoglycaemia have multiple insulinomas 
in the body and tail of the pancreas and are routinely treated 
by distal pancreatectomy with enucleation of any tumours in the
head or uncinate. Duodenotomy is not performed unless the
serum gastrin is elevated.
The likelihood of MEN-1 should be considered in any
patients with a PET. The possibility of and the need to detect
other endocrinopathies should be addressed. From a practical
viewpoint only a serum calcium test and prolactin test need to be
done routinely. Genetic testing is available and family members
should be screened if other endocrine tumours are found or the
family history is positive. As genetic testing becomes more
available, it will be feasible to perform a simple, inexpensive
reliable test on all PET patients.
IMAGING AND LOCALIZATION
Dynamic contrast abdominal computed tomographic (CT) scanning
with intravenous and oral contrast is recommended as a baseline
imaging technique for localizing and staging PET. Potential
liver metastases and peripancreatic lymph node enlargement
should be ruled out. Magnetic resonance imaging may also be
useful, particularly in looking for metastases27,28 and in delineating
the relationship of the mass to the pancreatic duct and major
vessels (Figs 4,5).
Somatostatin receptor scintigraphy (SRS or octreotide scan-
ning) with radiolabelled octreotide has proven to be a sensitive
localization tool and is now used routinely in staging patients
with PET. It will detect most primary tumours or metastases 1 cm
or larger. This technique relies on the fact that many PET
possess high densities of somatostatin receptors, thus identifying
primary tumours as well as hepatic and extrahepatic metas-
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Fig. 4. Magnetic resonance imaging scan. Axial T2 image demon-
strating a massive vasoactive intestinal polypeptide (VIP)-secreting
tumour found in a 41-year-old man who presented with profuse secretory
diarrhoea and a VIP level of 1460 pg/mL (normal: 0–75 pg/mL).
Fig. 5. Magnetic resonance imaging scan. Coronal T1 image demon-
strates the vasoactive intestinal polypeptide (VIP)-secreting tumour
(8.5 cm) within the head and neck of the pancreas. There is displacement
of the portal vein/superior mesenteric veins, but both remain patent.
tases.29,30 Somatostatin receptor scintigraphy allows for whole-
body assessment specific for neuroendocrine tumours that may
be significant for identifying extraduodenopancreatic disease.
The National Institutes of Health group determined that SRS
was the single most sensitive test for localizing both primary and
metastatic gastrinomas.29 In a study of 151 patients with gastrinoma,
SRS detected 79% of sporadic gastrinomas and 91% of MEN-1 gas-
trinomas.31 Our experience has been that most sporadic duodenal
gastrinomas are not localized by octreotide because of their
small size and that metastatic nodes are much more likely to be the
source of the positive study. The positive studies in MEN-1
patients are usually from the pancreatic PET. Somatostatin
receptor scintigraphy uptake is significantly less frequent in
insulinomas whereas EUS is much more sensitive for insulinomas.32
Endoscopic ultrasound has been shown by some groups to be
more sensitive than CT or arteriography combined, but is dependent
on operator experience as well as on the site and size of the neo-
plasm.33 Its sensitivity for endocrine pancreatic tumours is
higher than 75% and often reaches 90–100%. Endoscopic ultra-
sound is particularly good for detecting small PET in the head,
uncinate and body of the pancreas. Although some have
reported that 50% of duodenal gastrinomas are detected by
EUS,33,34 that has not been our experience. We have found that
most patients with ZES and a duodenal gastrinoma have a negative
EUS. The sensitivity of EUS for metastatic lymph nodes is
approximately 58%.35 If EUS detects an insulinoma, no other
localization study is needed. It detects nearly all tumours 4 mm or
larger within the pancreas. In sporadic gastrinoma patients a
negative pancreatic EUS should rule out pancreatic localization
because nearly all such tumours are 1 cm or larger. This con-
trasts to those in the duodenum, most of which are < 1 cm.
Intraoperative ultrasound (IOUS) can help visualize non-palpable
intrapancreatic insulinomas and gastrinomas and their relationships
to ducts and vessels. Smaller tumours in the duodenal wall and
lymph nodes are not routinely detected because of the heterogenous
sonographic background. A combination of IOUS and bimanual
palpation by an experienced surgeon can achieve high detection
rates of insulinomas36,37 and should be done if the tumour
remains occult after initial exploration.
Selective venous sampling (SVS) of the portal vein, although
more sensitive (70–90%), is invasive, technically challenging,38
expensive, potentially more morbid and often available in only a
few centres. The tumour drains its hormonal products into the
portal venous system causing a rise in concentration, thus
regionalizing the neoplasm. It has been largely supplanted by
hepatic venous sampling after selective arterial stimulation.
Selective pancreatic arterial stimulation with hepatic venous
sampling (Imamura Test) evaluates the appropriate hormone
levels after selected stimuli are injected at the time of pancreatic
arteriography. This technique does not localize tumours, rather
regionalizes the hypersecretion. Small doses of secretin or
calcium are injected sequentially into the superior mesenteric,
gastroduodenal and splenic arteries, with blood samples col-
lected from the hepatic vein. An increase in the level of gastrin
following secretin administration regionalizes a gastrinoma. An
increase in the level of insulin following calcium is indicative of an
insulinoma. In combination with intraoperative ultrasound this
can enhance surgical success.39
Selective pancreatic angiography is rarely used by itself, but may
be valuable when EUS is negative. A hypervascular blush is
seen around the tumour. This technique depends on the expertise
of the radiologist as well as on the size and neovascularity of the
primary tumour. Because angiography demonstrates fewer than
40% of insulinomas and gastrinomas,40 it is currently used only in
conjunction with selective arterial stimulation tests.
FOLLOW UP
Patients with PET need regular long-term follow up for recurrence
of tumour or metastases. Benign sporadic insulinoma patients
are the exception because they are generally cured by surgical
resection. Other patients with sporadic functional tumours
require annual specific hormone studies even if asymptomatic. The
MEN-1 patients need annual follow-up hormone studies and
periodic imaging with CT and octreotide scans. We currently
recommend EUS of the remaining pancreatic head even in the
asymptomatic patient. Recurrence should be aggressively
managed by re-resection or chemotherapy as dictated by the
original operation, tumour type and extent of recurrence.
CONCLUSIONS
Pancreatic endocrine tumours include a group of fascinating
functional tumours as well as a significant group without apparent
hormonal manifestations that are difficult to diagnose until they are
advanced locally or associated with liver or distant metastases.
Once the diagnosis has been made, surgical difficulties can
beset the most experienced of endocrine surgeons. These
include localization, function neutralization, extent of resec-
tion, treatment of liver metastases and appropriate chemotherapy.
Regrettably there is a paucity of prospective randomized trials on
which to establish appropriate ‘evidence-based surgery’.
Although rare, it is important for the general surgeon to be
aware of these tumours and be able to diagnose and treat appro-
priately. There is increasing evidence that with earlier diag-
nosis, improved localization or directed operative strategy
(duodenotomy for occult gastrinoma), lymphadenectomy when
appropriate, extensive palliative resections, use of long-acting
somatostatin analogues to inhibit hormonal secretion and
tumour growth, and embolization or ablation of liver metas-
tases, that the long-term results have improved during the past two
decades.
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